Avalo Therapeutics

Avalo Therapeutics, Inc. is a biopharmaceutical company. engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at Oppenheimer's 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 1:20 p.m. ET.

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a price to the public of $3.98 per share and warrant. The warrants have a one-year term and an exercise price of $5.00 per share. The offering is expected to close on February 7, 2023, subject to customary closing conditions.

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the shares and warrants in the proposed offering are to be sold by Avalo. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with Non-Eosinophilic Asthma (NEA). Avalo will allow additional patients currently in the run-in period to complete enrollment. Topline data from the clinical trial are expected to be released in the second quarter of 2023.

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2022.

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future payments for previously out-licensed assets including AVTX-007, AVTX-501, and AVTX-611 to ES Therapeutics, LLC (ES) in exchange for $5.0 million. The sale is expected to close in November.

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

The average of price targets set by Wall Street analysts indicates a potential upside of 191.3% in Avalo Therapeutics, Inc. (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know

WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein, AVTX-008, has now entered IND-enabling studies, with a target IND submission date of 2024. The company is currently evaluating a number of immune dysregulation disorders to pursue. BTLA is an immune checkpoint and a key component of the LIGHT-signaling network and complements AVTX-002, the company's fully human anti-LIGHT monoclonal antibody, currently in the Phase 2 PEAK Trial for non-eosinophilic asthma.

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.

Avalo to Present at the H.C. Wainwright Global Investment Conference

WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board. Mr. Boyd and Dr. Maher's resignations from the Board, effective August 8, 2022, did not arise from any disagreement with the Company, any member of the Board, or Company management regarding any matter related to the Company's operations, policies, practices, or otherwise.

Avalo Therapeutics Announces Board Changes

The consensus price target hints at a 230.1% upside potential for Avalo Therapeutics, Inc. (AVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should Know

WAYNE, Pa. and ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2022.

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Topline Pivotal trial results expected 1H2023 Topline Pivotal trial results expected 1H2023

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007 (camoteskimab), Avalo's anti-IL-18 monoclonal antibody product. Under the terms of the agreement, Apollo will assume responsibility for the future development of AVTX-007, including the ongoing clinical trial. Apollo will lead future clinical development in its selected therapeutic indications.

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022. The Company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on July 8, 2022, under the Company's existing trading symbol “AVTX”.

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 4:00 PM ET at the Marriott Marquis in New York, NY.

Avalo to Present at the 2022 Jefferies Healthcare Conference

Topline results expected 4Q2022 Topline results expected 4Q2022

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Life Sciences Conference being held May 23-26, 2022. The pre-recorded formal presentation will be made available on Tuesday, May 24, 2022 at 7:00 AM ET.

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

WAYNE, Pa. and ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and first quarter 2022 financial results.

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, announced today that members of its senior management team will present at Oppenheimer's 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 1:20 p.m. ET.

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

WAYNE, Pa. and ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet need in immunology and rare genetic diseases, today announced business updates and year-end financial results for 2021.

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

Promotes Dr. Garry Neil to Chief Executive Officer Promotes Chris Sullivan to Chief Financial Officer

Avalo Therapeutics Announces Leadership Transition

WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases announced today that members of its senior management team will present and host 1x1 meetings at the 2022 BIO CEO and Investor Conference being held at the Marriott Marquis in NYC on February 14-15, 2022 and virtually through February 17, 2022.

Avalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference

Announces inducement grant under NASDAQ Listing Rule 5635(c)(4) Announces inducement grant under NASDAQ Listing Rule 5635(c)(4)

Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer

WAYNE, Pa. and ROCKVILLE, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases, today provides a comprehensive update on the Company's growth opportunities and mid-stage development portfolio.

Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

News for Avalo Therapeutics Stock (AVTX)